Aspocomp Group Plc, Stock Exchange Release, February 25, 2026, at 9:15 a.m. Aspocomp Group Plc has published today its Remuneration Report for Governing Bodies 2025. The attached report is also available at the company’s website at www.aspocomp.com. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. ASPOCOMP GROUP PLC Manu SkyttäPresident and CEO Aspocomp – heart of your technology A printed circuit board (PCB) is used for electrical interconnection and as a component assembly platform in electronic devices. Aspocomp provides PCB technology design, testing and logistics services over the entire lifecycle of a product. The company’s own production and extensive international partner network guarantee cost-effectiveness and reliable deliveries. Aspocomp’s customers...

Baltic Horizon Capital AS announced an offering of up to 169,147,497 new units of Baltic Horizon Fund to the existing investors of Baltic Horizon Fund on 17 February 2026 and the offering period began on 23 February 2026. Some of the existing investors have experienced difficulties in subscribing for different reasons. Baltic Horizon Capital AS reminds and encourages the existing investors to contact the fund manager directly via info@baltichorizon.com in all such cases. For additional information, please contact: Tarmo KarotamBaltic Horizon Fund managerE-mail tarmo.karotam@baltichorizon.comwww.baltichorizon.com Baltic Horizon Fund is a registered contractual public closed-end real estate fund managed by Alternative Investment Fund Manager license holder Baltic Horizon Capital AS. Distribution: GlobeNewswire, Nasdaq Tallinn, www.baltichorizon.com To...

        Company Announcement No 06/2026Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 AL Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk25 February 2026  Dear Sirs AL Sydbank delivers strong first financial statements AL Sydbank’s first financial statements demonstrate that the Bank knows how to maintain momentum through the merger. The Bank has joined the ranks of the very largest financial institutions with a significantly larger customer base, higher credit intermediation and a decent return on equity. The financial statements for 2025 are the first for the new AL Sydbank. With its 1 million retail clients, 100,000 corporate clients and 20,000 associations, AL Sydbank is one of the banking heavyweights in Denmark, which is clearly reflected in its volume where credit intermediation totals DKK 384bn,...

COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO: “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of customers, innovation leadership and world-class scale capabilities, driving performance and strengthening resilience. In 2026, we expect another good year, with growth across all sales areas and margin expansion. We continue to execute...

Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO:”In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of customers, innovation leadership and world-class scale capabilities, driving performance and strengthening resilience. In 2026, we expect another good year, with growth across all sales areas and margin expansion. We continue to execute on our strategy, positioning us to firmly...

The Netherlands, 25 February 2026  Vopak reports record financial results for 2025 and announces shareholder distributions program of around EUR 1.7 billion through year-end 2030  Key highlights  ImproveNet profit -including exceptional items- FY 2025 increased by 61% to EUR 604 million and EPS of EUR 5.23 increased by 68% year-on-year Proportional operating free cash flow in FY 2025 increased to EUR 823 million leading to a record proportional operating free cash flow per share of EUR 7.13 per share, 7% increase year-on-year Proposed dividend for FY 2025 of EUR 1.80 per share, 12.5% increase year-on-year Well-positioned to achieve our ambition of investing EUR 4 billion by 2030, supporting our operating cash return range of 13% to 17% Shareholder distributions program of around EUR 1.7 billion through year-end 2030, consisting of an...

Bigbank started 2026 with strong growth and solid profitability. The growth of the loan portfolio was driven by the business loan portfolio, which increased by 62 million euros in January. The home loan portfolio grew by 9 million euros, while the consumer loan portfolio remained at the level of the end of 2025. In total, the loan portfolio increased by 71 million euros in the first month of the year, marking one of the largest monthly loan portfolio growth figures in Bigbank’s history. The deposit portfolio grew even more strongly in January. Bigbank’s attractive deposit interest rates continued to bring in a large number of customers in both term deposits and savings deposits. The bank also continued to increase current account balances in the Baltics under market‑leading interest conditions. The savings deposit portfolio increased by...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 6 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased...

Trondheim, 25 February 2026 NORBIT today announces that segment PIR is in advanced negotiations with a European client within defence and security regarding an order for contract manufacturing. The expected value of the order is approximately NOK 115 million, to be delivered in second quarter 2026. The potential contract follows another recently received award of approximately NOK 80 million for deliveries in the same quarter. “The strong activity in the defence and security market continues, and the delivery window remains short once contracts are awarded. This requires preparedness, scalable capacity and disciplined execution. Our strategic expansions have served us well in positioning NORBIT to deliver under these conditions. Agility and trust define successful partnerships in this market. Contributing to solutions that enhance security...

Vopak announces a multi-year share buyback program of up to EUR 500 million and commences the first tranche of up to EUR 100 million Rotterdam, the Netherlands, 25th February 2026 Vopak intends to commence a multi-year share buyback program of up to EUR 500 million, expected to be executed by year-end of 2030 in multiple tranches. This share buyback program is part of the shareholder distributions program of around EUR 1.7 billion through year-end 2030. In addition to the multi-year share buyback program, Vopak has enhanced the progressive dividend policy, through which the company intends to increase its dividend per share by 5% or more annually. For further details please refer to the FY 2025 press release published on 25 February 2026. The first tranche of the multi-year share buyback program, of up to EUR 100 million, will commence...